NXL
Nexalin Technology, Inc.
$0.4310
-8.88%
$8.9M
No data for this timeframe.
Vol
Market Cap$8.9M
Cap SizeNano Cap
Inst. Holders10 funds
Inst. Value$223.2K
Inst. Activity0 buys / 2 sells
SEC Reports4
Press Releases2
Exchange Nasdaq·Sector Electromedical & Electrotherapeutic Apparatus·Inc. DE·CIK 0001527352·Prev Close $0.4730
Recent Activity
May 19, 2026
SEC
Nexalin Technology acquired PONM, Inc. from GreenLight Ventures for $1.3 million in stock, gaining control of the AI-int
8-K — Impact 6/10
Apr 22, 2026
SEC
Nexalin Technology entered into a $944,820 agreement with Lindus Health to conduct a pivotal clinical trial for its HALO
8-K — Impact 5/10
Apr 22, 2026
SEC
Nexalin Technology (NXL) reported a Q4 2025 EPS miss of -27% versus consensus, with actual EPS of -$0.13 versus an estim
PRESS-RELEASE — Impact 6/10
Inst.
RENAISSANCE TECHNOLOGIES LLC — NEAR_EXIT
10,676 shares ($3.7K)
Inst.
FMR LLC — NEAR_EXIT
1,500 shares ($522.00)
Jun 10, 2026
Press
Nexalin announced positive results from an open-label pilot trial of its DIFS 15mA/77.5Hz neurostimulation platform in a
Impact 7/10
Jun 10, 2026
fda
Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan.
<p align="center"><em>Study using Nexalin’s proprietary DIFS</em>™<em> 15 mA 77.5 Hz treatment platf
May 19, 2026
Press
Nexalin Technology closed the $1.3M acquisition of PONM, Inc. and entered an exclusive license and strategic partnership
Impact 6/10
Price Targets
Historical data — last covering-analyst action Mar 2025. No current recommendation available.
$2.00 (Mar 2025)
Current $0.4310
Low $2.00
Median $2.00
High $2.00
1 analysts
$2.00
$2.00
Analyst Ratings
1Strong Buy
3Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 24, 2025 | Maxim Group | UPGRADE | Hold → Buy |
| Dec 5, 2024 | Maxim Group | DOWNGRADE | Buy → Hold |
| Oct 9, 2024 | Maxim Group | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.10 ▼ -11.1% | $-0.10 — $-0.10 | 0% YoY | 1 |
| Next Q | $-0.09 | $-0.09 — $-0.09 | 31% YoY | 1 |
| Current FY | $-0.38 ▼ -8.6% | $-0.38 — $-0.38 | 24% YoY | 1 |
| Next FY | $-0.31 | $-0.31 — $-0.31 | 18% YoY | 1 |
Latest Reports
BULLISH
Press
7/10
Nexalin announced positive results from an open-label pilot trial of its DIFS 15mA/77.5Hz neurostimulation platform in a
Jun 10, 2026
MIXED
8-K
6/10
Nexalin Technology acquired PONM, Inc. from GreenLight Ventures for $1.3 million in stock, gaining control of the AI-int
May 19, 2026
NEUTRAL
8-K
5/10
Nexalin Technology entered into a $944,820 agreement with Lindus Health to conduct a pivotal clinical trial for its HALO
Apr 22, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| PEAK6 LLC | $133.9K | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $44.0K | — |
| VANGUARD FIDUCIARY TRUST CO | $17.9K | — |
| STATE STREET CORP | $11.3K | ADD |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $7.3K | — |
10 institutional holders with $223.2K total value (664,339 shares) as of 2026-Q1. Top holders: PEAK6, VANGUARD, VANGUARD. Net selling activity: 2 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | PEAK6 LLC | 384,460 | $133.9K | 60.0% | — |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 126,536 | $44.0K | 19.7% | — |
| 3 | VANGUARD FIDUCIARY TRUST CO | 51,386 | $17.9K | 8.0% | — |
| 4 | STATE STREET CORP | 32,300 | $11.3K | 5.0% | ADD +92.3% |
| 5 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 20,928 | $7.3K | 3.3% | — |
| 6 | RAYMOND JAMES FINANCIAL INC | 12,100 | $4.2K | 1.9% | — |
| 7 | RENAISSANCE TECHNOLOGIES LLC | 10,676 | $3.7K | 1.7% | NEAR_EXIT -91.3% |
| 8 | FMR LLC | 1,500 | $522.00 | 0.2% | NEAR_EXIT -95.3% |
| 9 | WELLS FARGO & COMPANY/MN | 1,000 | $348.00 | 0.2% | — |
| 10 | HRT FINANCIAL LP | 23,453 | $8.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 122,100 | 10,676 | -91.3% | $3.7K | 2026-Q1 |
| FMR LLC | NEAR_EXIT | 31,625 | 1,500 | -95.3% | $522.00 | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 55,700 | 122,100 | +119.2% | $68.1K | 2025-Q4 |
| FMR LLC | DOUBLED | 1,400 | 31,625 | +2158.9% | $17.6K | 2025-Q4 |
| FMR LLC | DOUBLED | 100 | 1,400 | +1300.0% | $1.3K | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 15,085 | 440 | -97.1% | $403.00 | 2025-Q3 |
| VANGUARD GROUP INC | DOUBLED | 31,780 | 125,460 | +294.8% | $346.3K | 2024-Q4 |
| STATE STREET CORP | ADD | 16,800 | 32,300 | +92.3% | $89.1K | 2024-Q4 |
| ROYAL BANK OF CANADA | DOUBLED | 500 | 3,000 | +500.0% | $8.0K | 2024-Q4 |
| UBS Group AG | NEAR_EXIT | 2,466 | 140 | -94.3% | $386.00 | 2024-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 46 | 73 | +58.7% | $49.00 | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
4 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 1 mixed, 2 neutral. Avg impact: 5.3/10.
MIXED
8-K
6/10
Nexalin Technology acquired PONM, Inc. from GreenLight Ventures for $1.3 million in stock, gaining c
May 19, 2026
NEUTRAL
8-K
5/10
Nexalin Technology entered into a $944,820 agreement with Lindus Health to conduct a pivotal clinica
Apr 22, 2026
BEARISH
PRESS-RELEASE
6/10
Nexalin Technology (NXL) reported a Q4 2025 EPS miss of -27% versus consensus, with actual EPS of -$
Apr 22, 2026
NEUTRAL
8-K
4/10
Nexalin Technology announced the advancement of its planned pivotal clinical trial for the HALO Clar
Feb 25, 2026
Historical analyst distribution (last covering-analyst action Mar 2025): 80% buy across 5 analysts — 1 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Mar 2025. No current recommendation available.
$2.00 mean target (Mar 2025)
$2.00 Low
$2.00 High
| Metric | Value |
|---|---|
| Current Price | $0.4310 |
| Target Low | $2.00 |
| Target Mean | $2.00 |
| Target Median | $2.00 |
| Target High | $2.00 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.10 | $-0.10 | $-0.10 | 0.0% | -11.1% | 0↑ 1↓ | $0.0B | 27.5% | 1 |
| Next Q 2026-09-30 |
$-0.09 | $-0.09 | $-0.09 | 30.8% | +0.0% | — | $0.0B | 395.9% | 1 |
| Current FY 2026-12-31 |
$-0.38 | $-0.38 | $-0.38 | 24.0% | -8.6% | 0↑ 1↓ | $0.0B | 14.4% | 1 |
| Next FY 2027-12-31 |
$-0.31 | $-0.31 | $-0.31 | 18.4% | +0.0% | — | $0.0B | 100.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.100 | |
| 7d ago | $-0.090 | -0.010 |
| 30d ago | $-0.090 | -0.010 |
| 60d ago | $-0.100 | |
| 90d ago | $-0.100 |
1 analyst firms have rated this stock: 1 upgrades, 1 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 24, 2025 | Maxim Group | UPGRADE | Hold | Buy |
| Dec 5, 2024 | Maxim Group | DOWNGRADE | Buy | Hold |
| Oct 9, 2024 | Maxim Group | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% | |
| May 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% | |
| Apr 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% | |
| Mar 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% | |
| Feb 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% | |
| Jan 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 10, 2026
fda
Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan.
<p align="center"><em>Study using Nexalin’s proprietary DIFS</em>™<em> 15 mA 77.5 Hz treatment platform demonstrated rapid, large-magnitude improvemen
Jun 4, 2026
other
Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia
<p align="center"><em>Newly issued U.S. patent expected to provide core intellectual property protection through 2042, further strengthening Nexalin’s
May 22, 2026
short_volume
Short Volume: NXL — 57.4% short (2.8M / 4.9M)
Short: 2,788,153 | Exempt: 37,897 | TRF Vol: 4,859,670 | Short Ratio: 57.4% | Off-exchange volume (dark pool + OTC)
May 21, 2026
other
Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury
<p align="center">U.S. House Appropriations Committee report language directs VA to support additional research evaluating non-invasive deep brain neu
May 19, 2026
m_and_a
Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial
Acquisition gives Nexalin control of AI-integrated remote patient-monitoring, clinical data-capture and virtual-care infrastructure already deployed a
May 11, 2026
earnings_calendar
NXL Q1 2026 Earnings Scheduled — 2026-05-11
Apr 28, 2026
other
Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia
<p align="center"><em>Publication reports statistically significant improvement in sleep quality following treatment with Nexalin’s 15 mA, 77.5 Hz sti
Apr 22, 2026
earnings
Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment
160-participant, triple-blinded, sham-controlled study designed to support planned De Novo FDA submission for moderate-to-severe insomnia <pre>160-par
Apr 14, 2026
other
Join Nexalin’s Exclusive Live Investor Webinar and Q&A Session on April 21
<p>ORLANDO, FL, April 14, 2026 (GLOBE NEWSWIRE) -- RedChip Companies will host an investor webinar on April 21, 2026, at 4:15 p.m. ET with Nexalin T
Apr 9, 2026
other
Nexalin Announces Peer-Reviewed Study Showing the Company’s DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents
<p align="center"><i>BMC Psychiatry publication reports statistically significant reductions in self-injury behaviors and depressive symptoms, with br
Mar 12, 2026
earnings_calendar
NXL Q4 2025 Earnings Scheduled — 2026-03-12